New GLP-1 pill helps patients lose up to 8% of body weight, trial shows

A clinical trial found that orforglipron, a new GLP-1 pill developed by Eli Lilly, led to greater weight loss than semaglutide tablets, with patients losing up to 8% of their body weight. The drug, which is not yet approved in the UK, US, or Europe, could offer a more effective oral alternative to injections for weight loss and diabetes management. While it showed promising results, discontinuation rates were higher due to side effects, highlighting the need for stricter controls and further research on long-term safety and effectiveness.